Matthew C. Abernethy serves as the Chief Financial Officer at Neurocrine Biosciences Inc., a position he has held since joining the company in 2019. With a robust background in finance and strategic planning within the biotechnology sector, Abernethy has been instrumental in steering Neurocrine Biosciences through significant growth and development phases. Prior to his role at Neurocrine, he held the position of Chief Financial Officer at Juno Therapeutics, where he played a pivotal role in the company's financial strategy and its eventual acquisition by Celgene Corporation for $9 billion in 2018. His experience also includes a tenure at Amgen, where he held various leadership roles in finance and corporate development, contributing to the company's global expansion and operational efficiency. In his current role at Neurocrine Biosciences, Abernethy oversees all financial aspects of the company, including financial planning and analysis, accounting, and investor relations. His strategic vision has been crucial in driving the company's financial health and supporting its mission to develop treatments for neurological and endocrine-related diseases. Under his leadership, Neurocrine Biosciences has successfully launched several key products, including Ingrezza, a treatment for tardive dyskinesia, and Orilissa, a treatment for endometriosis. Abernethy's ability to navigate complex financial landscapes and his commitment to fostering innovation have solidified his reputation as a key leader in the biotechnology industry.